SHC
Company Description
Sotera Health Company, headquartered in Broadview Heights, Ohio, delivers essential sterilization, laboratory testing, and advisory services to a global clientele spanning North America, Europe, and various international regions. The firm's sterilization capabilities encompass gamma and electron beam irradiation, alongside ethylene oxide (EO) processing. Through its Nelson Labs division, Sotera Health conducts comprehensive microbiological and analytical chemistry analyses. Additionally, it offers specialized consulting to the medical device and biopharmaceutical industries. Sotera Health serves a diverse array of sectors, including medical device manufacturers, pharmaceutical companies, producers of food and agricultural products, and various commercial, advanced, and specialty application industries. Incorporated in 2017, the company was previously known as Sotera Health Topco, Inc., adopting its current name in October 2020.
Track Record
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1.16B | 1.10B | 1.05B | 1.00B | 931.48M | 818.16M | 778.33M | 746.15M |
| Net Income | 77.95M | 44.40M | 51.38M | (233.57M) | 116.88M | (38.62M) | (20.85M) | (5.87M) |
| EPS | 0.27 | 0.16 | 0.18 | -0.83 | 0.41 | -0.14 | -0.07 | -0.02 |
| Free Cash Flow | 149.18M | 45.09M | (362.71M) | 95.58M | 179.38M | 67.08M | 91.78M | 46.95M |
| FCF / Share | 0.53 | 0.16 | -1.29 | 0.34 | 0.64 | 0.24 | 0.32 | 0.19 |
| Operating CF | 287.19M | 224.16M | (147.73M) | 277.96M | 281.55M | 120.58M | 149.04M | 119.56M |
| Total Assets | 3.26B | 3.07B | 3.13B | 3.12B | 2.79B | 2.76B | 2.58B | 2.71B |
| Total Debt | 2.27B | 2.35B | 2.33B | 2.03B | 1.83B | 1.91B | 2.85B | 2.24B |
| Cash & Equiv | 346.46M | 277.24M | 296.41M | 395.21M | 106.92M | 102.45M | 62.86M | 96.27M |
| Book Value | 606.03M | 404.91M | 443.73M | 350.24M | 586.10M | 452.30M | (642.57M) | 44.36M |
| Return on Equity | 0.13 | 0.11 | 0.12 | -0.67 | 0.20 | -0.09 | N/A | -0.13 |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 321.38M | 280.05M | 303.44M | 311.31M | 294.34M | 254.52M | 290.20M | 285.47M | 276.59M | 248.18M | 310.24M | 263.18M |
| Net Income | 53.64M | 26.59M | 34.85M | 48.40M | 7.96M | (13.26M) | 12.32M | 17.00M | 8.75M | 6.32M | 38.68M | (13.66M) |
| EPS | 0.19 | 0.09 | 0.12 | 0.17 | 0.03 | -0.05 | 0.04 | 0.06 | 0.03 | 0.02 | 0.14 | -0.05 |
| Free Cash Flow | 42.05M | (16.73M) | 52.41M | 34.98M | 26.19M | 35.60M | (10.15M) | 59.21M | 19.37M | (25.19M) | 48.30M | (10.17M) |
| FCF / Share | 0.15 | -0.06 | 0.18 | 0.12 | 0.09 | 0.13 | -0.04 | 0.21 | 0.07 | -0.09 | 0.17 | -0.04 |
| Operating CF | 88.50M | 29.43M | 103.10M | 71.15M | 57.42M | 55.52M | 55.72M | 95.60M | 61.30M | 9.70M | 113.12M | 41.85M |
| Total Assets | 3.31B | 3.24B | 3.26B | 3.19B | 3.22B | 3.10B | 3.07B | 3.15B | 3.06B | 3.06B | 3.13B | 3.04B |
| Total Debt | 2.27B | 2.27B | 2.27B | 2.28B | 2.35B | 2.35B | 2.35B | 2.36B | 2.35B | 2.35B | 2.33B | 2.33B |
| Cash & Equiv | 356.73M | 315.94M | 346.46M | 301.03M | 332.44M | 304.39M | 277.24M | 306.74M | 246.08M | 261.13M | 296.41M | 244.96M |
| Book Value | 665.65M | 622.50M | 606.03M | 550.47M | 511.28M | 414.09M | 404.91M | 470.16M | 422.76M | 429.39M | 443.73M | 377.47M |
| Return on Equity | 0.08 | 0.04 | 0.06 | 0.09 | 0.02 | -0.03 | 0.03 | 0.04 | 0.02 | 0.01 | 0.09 | -0.04 |
